Drug - Kapvay (clonidine) [Shionogi Pharmaceuticals]
Therapeutic area - ADHD
- Patient is ≥ 3 years of age AND
- Patient is being treated for Attention Deficit Hyperactivity Disorder (ADHD) AND
- Patient shows some therapeutic benefit of an immediate release clonidine tablet taken at least three times daily and there is a therapeutic need to administer the clonidine twice daily
No approvals will be granted to patients under the age of 3.
120 per month
Kapvay is an extended-release clonidine tablet indicated for use in patients with ADHD. Kapvay requires twice daily dosing and, in a head to head pharmacokinetic study with IR clonidine, has been shown to have a similar elimination half-life when administered at the same milligram amount.
At this time, it has not been definitively shown that Kapvay offers a cost or clinical benefit compared to clonidine IR. However, it represents a large cost increase compared to clonidine IR, at about $2.50/tablet (up to 4 tabs/day could be used). It is also important to consider that 1,359 clonidine tablet claims (66% of the total) are used in recipients <20 years of age, suggesting that the IR formulation is being used for ADHD.
MHCP Provider Call Center 651-431-2700 or 800-366-5411